Inflation-hedging properties of regional Chinese real estate market: evidence from 35 cities in China

The housing markets in China have been gaining considerable interest from investors, but the inflation-hedging characteristics of housing remain ambiguous. Based on Chinese city-level data, this study evaluates different inflation-hedging properties in eastern, middle and western real estate markets using panel vector autoregressive (PVAR) models. Findings suggest middle real estate markets afford the best hedging opportunities for expected inflation, which is robust considering housing market heterogeneity, financial crisis and the 2010 purchase restriction order. Moreover, hedging efficacy of anticipated inflation differs between markets with low and high supply–demand ratio

Conceptual mechanization studies for a horizon definition spacecraft attitude control subsystem, phase A, part II, 10 October 1966 - 29 May 1967

Attitude control subsystem for spin stabilized spacecraft for mapping earths infrared horizon radiance profiles in 15 micron carbon dioxide absorption ban

Semiarid watershed response in central New Mexico and its sensitivity to climate variability and change

Hydrologic processes in the semiarid regions of the Southwest United States are considered to be highly susceptible to variations in temperature and precipitation characteristics due to the effects of climate change. Relatively little is known about the potential impacts of climate change on the basin hydrologic response, namely streamflow, evapotranspiration and recharge, in the region. In this study, we present the development and application of a continuous, semi-distributed watershed model for climate change studies in semiarid basins of the Southwest US. Our objective is to capture hydrologic processes in large watersheds, while accounting for the spatial and temporal variations of climate forcing and basin properties in a simple fashion. We apply the model to the Río Salado basin in central New Mexico since it exhibits both a winter and summer precipitation regime and has a historical streamflow record for model testing purposes. Subsequently, we use a sequence of climate change scenarios that capture observed trends for winter and summer precipitation, as well as their interaction with higher temperatures, to perform long-term ensemble simulations of the basin response. Results of the modeling exercise indicate that precipitation uncertainty is amplified in the hydrologic response, in particular for processes that depend on a soil saturation threshold. We obtained substantially different hydrologic sensitivities for winter and summer precipitation ensembles, indicating a greater sensitivity to more intense summer storms as compared to more frequent winter events. In addition, the impact of changes in precipitation characteristics overwhelmed the effects of increased temperature in the study basin. Nevertheless, combined trends in precipitation and temperature yield a more sensitive hydrologic response throughout the year

Solving the riddle of codon usage preferences: a test for translational selection

Translational selection is responsible for the unequal usage of synonymous codons in protein coding genes in a wide variety of organisms. It is one of the most subtle and pervasive forces of molecular evolution, yet, establishing the underlying causes for its idiosyncratic behaviour across living kingdoms has proven elusive to researchers over the past 20 years. In this study, a statistical model for measuring translational selection in any given genome is developed, and the test is applied to 126 fully sequenced genomes, ranging from archaea to eukaryotes. It is shown that tRNA gene redundancy and genome size are interacting forces that ultimately determine the action of translational selection, and that an optimal genome size exists for which this kind of selection is maximal. Accordingly, genome size also presents upper and lower boundaries beyond which selection on codon usage is not possible. We propose a model where the coevolution of genome size and tRNA genes explains the observed patterns in translational selection in all living organisms. This model finally unifies our understanding of codon usage across prokaryotes and eukaryotes. Helicobacter pylori, Saccharomyces cerevisiae and Homo sapiens are codon usage paradigms that can be better understood under the proposed model

Eye-Safe Solid-State Quasi-CW Raman Laser with Millisecond Pulse Duration

We demonstrate the first quasi-CW (ms-long pulses, pump duty cycle of 10%) end-diode pumped solid state laser generating eye-safe radiation via intracavity Raman conversion. The output power at the first Stokes wavelength (1524 nm) was 250 mW. A theoretical model was applied to analyze the laser system and provide routes for optimization. The possibility of true CW operation was discussed.Comment: Preprint accepted for publication in Optics Communications on Feb 6, 201

Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis

Novel drugs to treat human African trypanosomiasis (HAT) are still urgently needed despite the recent addition of nifurtimox-eflornithine combination therapy (NECT) to WHO Model Lists of Essential Medicines against second stage HAT, where parasites have invaded the central nervous system (CNS). The pharmacology of a potential orally available lead compound, N-methoxy-6-{5-[4-(N-methoxyamidino) phenyl]-furan-2-yl}-nicotinamidine (DB844), was evaluated in a vervet monkey model of second stage HAT, following promising results in mice. DB844 was administered orally to vervet monkeys, beginning 28 days post infection (DPI) with Trypanosoma brucei rhodesiense KETRI 2537. DB844 was absorbed and converted to the active metabolite 6-[5-(4-phenylamidinophenyl)-furanyl-2-yl]-nicotinamide (DB820), exhibiting plasma C(max) values of 430 and 190 nM for DB844 and DB820, respectively, after the 14th dose at 6 mg/kg qd. A 100-fold reduction in blood trypanosome counts was observed within 24 h of the third dose and, at the end of treatment evaluation performed four days post the last drug dose, trypanosomes were not detected in the blood or cerebrospinal fluid of any monkey. However, some animals relapsed during the 300 days of post treatment monitoring, resulting in a cure rate of 3/8 (37.5%) and 3/7 (42.9%) for the 5 mg/kg×10 days and the 6 mg/kg×14 days dose regimens respectively. These DB844 efficacy data were an improvement compared with pentamidine and pafuramidine both of which were previously shown to be non-curative in this model of CNS stage HAT. These data show that synthesis of novel diamidines with improved activity against CNS-stage HAT was possible

Generation of a wave packet tailored to efficient free space excitation of a single atom

We demonstrate the generation of an optical dipole wave suitable for the process of efficiently coupling single quanta of light and matter in free space. We employ a parabolic mirror for the conversion of a transverse beam mode to a focused dipole wave and show the required spatial and temporal shaping of the mode incident onto the mirror. The results include a proof of principle correction of the parabolic mirror's aberrations. For the application of exciting an atom with a single photon pulse we demonstrate the creation of a suitable temporal pulse envelope. We infer coupling strengths of 89% and success probabilities of up to 87% for the application of exciting a single atom for the current experimental parameters.Comment: to be published in Europ. Phys. J.

3 W of single-frequency output at 532 nm by intracavity frequency doubling of a diode-bar-pumped Nd:YAG ring laser 3 W of single-frequency output at 532 nm by intracavity frequency doubling of a diode-bar-pumped Nd:YAG ring laser

A beam-shaped 20W diode-bar has longitudinally pumped a Nd:YAG laser in a ring configuration. Unidirectional single-frequency operation is enforced by a Faraday rotator. Intracavity frequency doubling, using a KTP crystal has produced 3W of stable, single-frequency TEMoo output at 532nm

Efficacy, safety, and dose of Pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies

Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in African patients with first stage HAT.; The Phase 2a study was an open-label, non-controlled, proof-of-concept study where 32 patients were treated with 100 mg of pafuramidine orally twice a day (BID) for 5 days at two trypanosomiasis reference centers (Angola and the Democratic Republic of the Congo [DRC]) between August 2001 and November 2004. The Phase 2b study compared pafuramidine in 41 patients versus standard pentamidine therapy in 40 patients. The Phase 2b study was open-label, parallel-group, controlled, randomized, and conducted at two sites in the DRC between April 2003 and February 2007. The Phase 2b study was then amended to add an open-label sequence (Phase 2b-2), where 30 patients received pafuramidine for 10 days. The primary efficacy endpoint was parasitologic cure at 24 hours (Phase 2a) or 3 months (Phase 2b) after treatment completion. The primary safety outcome was the rate of occurrence of World Health Organization Toxicity Scale Grade 3 or higher adverse events. All subjects provided written informed consent.; Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing. The cure rates 3 months post-treatment were 79% in the 5-day pafuramidine, 100% in the 7-day pentamidine, and 93% in the 10-day pafuramidine groups. In Phase 2b, the percentage of patients with at least 1 treatment-emergent adverse event was notably higher after pentamidine treatment (93%) than pafuramidine treatment for 5 days (25%) and 10 days (57%). These results support continuation of the development program for pafuramidine into Phase 3